Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)
Enlivex Therapeutics Ltd. is a clinical-stage biotech company specializing in the development of immune rebalancing immunotherapies for the treatment of severe inflammatory and immune-related conditions. Their flagship product pipeline focuses on harnessing the body's immune system to improve outcomes in conditions such as sepsis, graft-versus-host disease, and other immune dysregulation disorders.
Company News
Enlivex Therapeutics reported positive Phase I/II trial results for Allocetra, showing significant pain reduction and functional improvement in knee osteoarthritis patients, with a favorable safety profile.
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup cut the price target for Starbucks Corporation (NASDAQ: SBUX) from $102 to $95. Citigroup analyst Jon Tower maintained a Neutral rating. Starbucks...